Even though the collective evidence supports the efficacy of CXCR4 inhibitors as therapies for cancer and HIV-1 treatments, important challenges stay before CXCR4 inhibitors will be sanctioned for clinical use, because of the ubiquitous expression of CXCR4 in normal tissues as well as the functional need for the CXCR4CSDF-1 interaction, as discussed with this review
Even though the collective evidence supports the efficacy of CXCR4 inhibitors as therapies for cancer and HIV-1 treatments, important challenges stay before CXCR4 inhibitors will be sanctioned for clinical use, because of the ubiquitous expression of CXCR4 in normal tissues as well as the functional need for the CXCR4CSDF-1 interaction, as discussed with this review.…